Abstract summary 

Current post-exposure prophylaxis for rabies virus infection has several limitations in terms of supply, cost, safety, and efficacy. Attempts to replace human or equine rabies immune globulins (HRIG or ERIG) have been made by several companies and institutes. We developed potent monoclonal antibodies to neutralize a broad spectrum of rabies viruses by screening hybridomas received from the U.S. Centers for Disease Control and Prevention (CDC). Two kinds of chimeric human antibodies (chimeric #7 and #17) were constructed by cloning the variable regions from selected hybridomas and the constant region of a human antibody. Two antibodies were bound to antigenic site III and I/IV, respectively, and were able to neutralize 51 field isolates of rabies virus that were isolated at different times and places such as Asia, Africa, North America, South America, and Australia. These two antibodies neutralize rabies viruses with high efficacy in an in vivo test using Syrian hamster and mouse models and show low risk for adverse immunogenicity.

Authors & Co-authors:  Kim Pan Kyeom PK Keum Sun Ju SJ Osinubi Modupe O V MOV Franka Richard R Shin Ji Young JY Park Sang Tae ST Kim Man Su MS Park Mi Jung MJ Lee Soo Young SY Carson William W Greenberg Lauren L Yu Pengcheng P Tao Xiaoyan X Lihua Wang W Tang Qing Q Liang Guodong G Shampur Madhusdana M Rupprecht Charles E CE Chang Shin Jae SJ

Study Outcome 

Source Link: Visit source